A Phase 2 interventional study of ombitasvir/paritaprevir/ritonavir and dasabuvir and Sofosbuvir in Chronic Hepatitis C Infection, sponsored by AbbVie. Completed. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2017-12-20.
Sponsored by AbbVie · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing ombitasvir in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. ombitasvir · Hepatitis C, Chronic.
Among the 19 studies testing ombitasvir in Hepatitis C, Chronic, this one is the 16th largest by enrollment, is one of 7 that started in 2015, is one of 7 in phase 2, and was the 11th registered.
950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.
Browse Hepatitis C, Chronic studies →None of the 19 studies testing ombitasvir in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →
ombitasvir: first FDA approval 2014 (VIEKIRA PAK (COPACKAGED)), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 8 · Phase 3 11 · Phase 4 1
First in 2011; this study’s year is marked. 7 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 29 is below the median of 90 across 696 interventional studies indexed under Hepatitis C, Chronic.
Median enrollment 148 across the 19 interventional studies. Of the 18 that completed or were terminated, 16 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 19 have an industry lead sponsor. The 5 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
83 studies in Hepatitis C, Chronic by AbbVie: none open now, none under way, none of them phase 3. Of 82 finished, 74 (90%) have results posted.
Among the 83 studies in Hepatitis C, Chronic by AbbVie, this one is the 52nd largest by enrollment of the 58 interventional ones that give a count, is one of 25 that started in 2015, is one of 13 in phase 2, and was the 29th registered.
AbbVie’s Hepatitis C, Chronic studies by the year they started, since 2009.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing ombitasvir in Hepatitis C, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 83 in Hepatitis C, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and efficacy of ombitasvir/paritaprevir/ritonavir and dasabuvir with or without sofosbuvir (SOF) and ribavirin (RBV) in DAA treatment-experienced adults with Genotype 1 Chronic Hepatitis C Virus infection. This study will contain 2 parts.
Part 1: Approximately 20 participants and at least 10 of the 20 participants previously treated with the combination of ombitasvir/paritaprevir/ritonavir and dasabuvir, with or without RBV, and experienced treatment failure.
Part 2: Approximately 10 participants and all participants previously treated with SOF/ledipasvir and experienced treatment failure.
Efficacy, safety, and demographic analyses were performed separately for the 2 study parts using the intent-to-treat (ITT) population, which consists of all enrolled participants who received at least one dose of study drug.
950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.
This study's enrollment of 29 is below the median of 90 across 696 interventional studies indexed under Hepatitis C, Chronic.
Browse Hepatitis C, Chronic studies →AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
Compared within Hepatitis C, Chronic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hepatitis C. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
3-DAA (ombitasvir/paritaprevir/ritonavir once daily \[QD\] and dasabuvir twice daily \[BID\]) with and without sofosbuvir (SOF) QD and with or without ribavirin (RBV) BID for 12 or 24 weeks
Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir · Drug: Sofosbuvir · Drug: Ribavirin
Drug pages: Ombitasvir · Paritaprevir · Ritonavir · Dasabuvir
tablet, ombitasvir coformulated with paritaprevir and ritonavir; tablet, dasabuvir
Also known as: ABT-450/r/ABT-267, Viekira Pak, paritaprevir also known as ABT-450, ombitasvir also known as ABT-267, dasabuvir also known as ABT-333
tablet
Also known as: Sovaldi
tablet
Also known as: RBV
Percentage of Part 1 Participants With Sustained Virologic Response 12 (SVR12) Weeks Posttreatment
SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification \[\<LLOQ\]) 12 weeks after the last dose of study drug.
Time frame: 12 weeks after the last dose of active drug
Percentage of Part 2 Participants With Sustained Virologic Response 12 (SVR12) Weeks Post-treatment
SVR12 was defined as plasma HCV RNA level \<LLOQ 12 weeks after the last dose of study drug
Time frame: 12 weeks after the last dose of active drug
Percentage of Participants With On-treatment Virologic Failure
On-treatment virologic failure was defined as confirmed HCV RNA ≥ LLOQ after \< LLOQ during treatment, confirmed increase of \> 1 log (subscript)10(subscript) IU/mL above the lowest post-baseline HCV RNA during treatment, or HCV RNA ≥ LLOQ persistently during treatment with at least 6 weeks of treatment.
Time frame: Up to week 24
Percentage of Participants With Post-Treatment Relapse
Post-treatment relapse was defined as confirmed HCV RNA ≥ LLOQ between end of treatment and 12 weeks after the last dose of study drug among participants completing treatment and with HCV RNA \< LLOQ at the end of treatment.
Time frame: Within 12 weeks after the last actual dose of active study drug
Efficacy, safety, and demographic analyses were performed separately for the 2 study parts using the intent-to-treat (ITT) population, which consists of all enrolled participants who received at least one dose of study drug.
| Milestone | Part 1, 3-DAA With SOF With or Without RBV | Part 2, 3-DAA With RBV |
|---|---|---|
| Started | 22 | 7 |
| Completed | 20 | 6 |
| Not completed | 2 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Re-entered treatment in a previous study | 1 | 0 |
| Withdrew: Site closure | 1 | 0 |
SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification \[\<LLOQ\]) 12 weeks after the last dose of study drug.
| percentage of participants | Part 1, 3-DAA With SOF With or Without RBV |
|---|---|
| Percentage of Part 1 Participants With Sustained Virologic Response 12 (SVR12) Weeks Posttreatment | 95.5 (78.2 to 99.2) |
SVR12 was defined as plasma HCV RNA level \<LLOQ 12 weeks after the last dose of study drug
| percentage of participants | Part 2, 3-DAA With RBV |
|---|---|
| Percentage of Part 2 Participants With Sustained Virologic Response 12 (SVR12) Weeks Post-treatment | 85.7 (48.7 to 97.4) |
On-treatment virologic failure was defined as confirmed HCV RNA ≥ LLOQ after \< LLOQ during treatment, confirmed increase of \> 1 log (subscript)10(subscript) IU/mL above the lowest post-baseline HCV RNA during treatment, or HCV RNA ≥ LLOQ persistently during treatment with at least 6 weeks of treatment.
| percentage of participants | Part 1, 3-DAA With SOF With or Without RBV | Part 2, 3-DAA With RBV |
|---|---|---|
| Percentage of Participants With On-treatment Virologic Failure | 0.0 (0.0 to 14.9) | 14.3 (2.6 to 51.3) |
Post-treatment relapse was defined as confirmed HCV RNA ≥ LLOQ between end of treatment and 12 weeks after the last dose of study drug among participants completing treatment and with HCV RNA \< LLOQ at the end of treatment.
| percentage of participants | Part 1, 3-DAA With SOF With or Without RBV | Part 2, 3-DAA With RBV |
|---|---|---|
| Percentage of Participants With Post-Treatment Relapse | 4.8 (0.8 to 22.7) | 0.0 (0.0 to 39.0) |
Collected over Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from the time of study drug administration until 30 days after the last dose of study drug (up to 28 weeks).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1, 3-DAA With SOF With or Without RBV | — | 2/22 (9.1%) | 20/22 (90.9%) |
| Part 2, 3-DAA With RBV | — | 0/7 (0%) | 6/7 (85.7%) |
| Event | Part 1, 3-DAA With SOF With or Without RBV | Part 2, 3-DAA With RBV |
|---|---|---|
| CELLULITISInfections and infestations | 1/22 | 0/7 |
| PNEUMONIAInfections and infestations | 1/22 | 0/7 |
| Event | Part 1, 3-DAA With SOF With or Without RBV | Part 2, 3-DAA With RBV |
|---|---|---|
| FATIGUEGeneral disorders | 7/22 | 3/7 |
| HEADACHENervous system disorders | 8/22 | 1/7 |
| DIARRHOEAGastrointestinal disorders | 4/22 | 1/7 |
| INSOMNIAPsychiatric disorders | 4/22 | 0/7 |
| ANAEMIABlood and lymphatic system disorders | 0/22 | 1/7 |
| GASTROOESOPHAGEAL REFLUX DISEASEGastrointestinal disorders | 1/22 | 1/7 |
| IMPAIRED GASTRIC EMPTYINGGastrointestinal disorders | 0/22 | 1/7 |
| MALAISEGeneral disorders | 0/22 | 1/7 |
| CONJUNCTIVITIS BACTERIALInfections and infestations | 0/22 | 1/7 |
| MUSCLE STRAINInjury, poisoning and procedural complications | 1/22 | 1/7 |
| Age, Continuous(years) | Part 1, 3-DAA With SOF With or Without RBV | Part 2, 3-DAA With RBV | Total |
|---|---|---|---|
| Mean | 58.0 ± 6.41 | 65.3 ± 9.60 | NA ± NA |
| Sex: Female, Male(Participants) | Part 1, 3-DAA With SOF With or Without RBV | Part 2, 3-DAA With RBV | Total |
|---|---|---|---|
| Female | 7 | 1 | 8 |
| Male | 15 | 6 | 21 |
No study locations are listed for this record.
Ran from Feb 2015 to primary completion in Oct 2016, 20 months.
Results were first posted in Nov 2017, 1 year after primary completion.
Of 28 industry-sponsored phase 2 interventional studies under Hepatitis C, Chronic, half reached primary completion within 16 months of starting (the median); a quarter within 10 and three quarters within 28. This study's 20 months is above that.
Counting every sponsor, half of 35 studies reached it within 17 months; a quarter within 11 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ombitasvir · Paritaprevir · Ritonavir · Dasabuvir · Sofosbuvir · Ribavirin